Wilac D001 (Weissella confusa WIKIM51) supplementation significantly reduced triglyceride levels and improved abdominal fat distribution in overweight adults over 12 weeks, with supporting evidence from in vitro GLP-1 secretion and improved glucose tolerance in high-fat diet-fed mice.
Wilac D001 significantly increased GLP-1 secretion in STC-1 enteroendocrine cells compared to control.
High-fat diet-fed mice administered Wilac D001 showed lower fasting blood glucose levels and more rapid glucose recovery during an oral glucose tolerance test.
Wilac D001 supplementation led to a significant reduction in triglyceride levels in overweight adults in the clinical trial.
Wilac D001 supplementation was associated with improvements in total abdominal fat area, visceral fat area, and subcutaneous fat area in overweight adults.
No serious adverse events were reported during the 12-week clinical trial of Wilac D001 supplementation.
This research suggests that a probiotic called Wilac D001, made from the bacterial strain Weissella confusa WIKIM51, may help improve certain metabolic markers in overweight adults. In a 12-week clinical trial where participants took either the probiotic (at a dose of 10 billion bacteria per day) or a placebo, those taking Wilac D001 showed meaningful reductions in blood triglyceride levels and improvements in abdominal fat, including both visceral fat (the metabolically harmful fat around internal organs) and subcutaneous fat (the fat under the skin). No serious side effects were reported. The researchers also conducted laboratory and animal studies to explore how this probiotic might work. In cell-based experiments, Wilac D001 stimulated the release of a gut hormone called GLP-1, which plays a role in regulating blood sugar and metabolism. In mice fed a high-fat diet, the probiotic led to lower fasting blood sugar and faster normalization of blood sugar after a glucose challenge, suggesting improved glucose handling. This research suggests that Wilac D001 could be a useful tool for supporting metabolic health in overweight individuals, potentially acting through gut hormone pathways. However, since this was a single trial, larger and longer studies would be needed to confirm these findings and better understand the long-term effects and the specific biological mechanisms involved.
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.
Upload Your LabsPark S, Lee B, Sun H, Shin W, Mok J, Seo J, et al.. (2026). Effects of Wilac D001 (Weissella confusa WIKIM51) Supplementation on Metabolic Parameters and Central Adiposity in Overweight Adults: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.. Journal of microbiology and biotechnology. https://doi.org/10.4014/jmb.2606.06054